The recent understanding that FRDA disease pathogenesis involves GAA expansion-induced histone deacetylation of the FXN gene has now led to the proposed use of HDAC inhibitors for FRDA therapy (Gottesfeld and Pandolfo, 2009). Here, FXN is linked to Friedreich ataxia.